Strides Pharma Science (NSE:STAR) Short Ratio


NSE:STAR Strides Pharma Science Ltd NSE:STAR
69 GF Score
Price ₹1,082.60
GF Value ₹779.15
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Strides Pharma Science Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

NSE:STAR
69GF Score
Strides Pharma Science Ltd NSE:STAR
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Strides Pharma Science (NSE:STAR) Overvalued in 2026?

Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued. The current stock price of ₹1,082.60 is trading 38.9% above its estimated GF Value™ of ₹779.15. GuruFocus considers Strides Pharma Science to be Significantly Overvalued.

Key valuation signals for NSE:STAR:

  • Short Ratio:
  • GF Value™: ₹779.15 vs. price of ₹1,082.60 (38.9% above fair value)
  • GF Score™: 69/100 with 4 warning signs

No single metric tells the full story. See the NSE:STAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Strides Pharma Science Business Description

Other Exchanges 532531:India
Address Bannerghatta Road, Strides House, Bilekahalli, Bengaluru, KA, IND, 560076
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
69GF Score

Get the complete analysis for NSE:STAR

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,082.60
Price
₹779.15
GF Value